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This thesis develops an approach to enhance drug delivery to bone tumors by 
implementing a non-invasive mechanical loading technique. An imaging protocol that 
characterizes the load-enhanced drug uptake is also presented. The long-term goal of this work is 
to develop a clinical protocol that enhances the delivery of therapeutic agents to bone tumors by 
utilizing load-bearing activity. This easy-to-implement approach could help increase drug uptake 
into the tumor interstitial fluid space as well as into tumor cells, thereby enhancing a drug’s 
clinical effect while decreasing systemic drug dosage and unwanted side effects.  This thesis 
details the process used to grow cancer cells, induce tumors in a rat model, measure tumor 
development, inject a radioactive tracer, apply mechanical loading non-invasively, and image 
and quantify drug uptake distribution in bone tumors. Assessment of 
99m
Tc-labeled pamidronate 
uptake was completed in vivo using planar microSPECT (2D gamma camera scans) employing a 
rat model of bone metastases. The pilot study using this methodology demonstrated that non-
invasive mechanical loading enhanced drug delivery to cancerous tibial tumors by 34% when 
compared to contralateral non-loaded, non-tumor bearing tibiae. Several improvements to this 
approach have been developed including 1) improved cancer cell viability after injection, 2) 
enhancement of cancer cell inoculation by arthrotomy surgery instead of direct tibial injection, 3) 
shifting from gamma camera to 3D microPET imaging, 4) use of tumor-bearing tibiae as 
controls, 5) use of the clinically relevant Herceptin as the injected drug, and 6) implementation 
of high-resolution microCT and histology to assess bone destruction from tumor growth.  If 
additional studies in the rat model using these improved techniques demonstrate load-induced 
enhancement of drug delivery, the approach will be attempted in the clinic.  Clinical studies will 
implement exercise and/or non-invasive mechanical activity to enhance drug delivery.  If 
successful, this approach would result in an improvement in the quality of life of patients 











Chapter 1 Introduction, Background and Significance 
 
1.1 Introduction to project 
The side effects caused by chemotherapy in patients suffering from cancer are directly 
related to the body’s systemic drug concentration. The physical side effects experienced by 
patients add to psychological damage that can further affect the patient’s quality of life. Many 
approaches have been explored in cancer research to increase tumor drug concentration to 
increase a drug’s therapeutic effects so that systemic drug dosage and unwanted side effects can 
be reduced. The objective of this work is to target bone cancers and improve local drug uptake 
into tumor cells and their environment. This thesis project utilizes the well-established skeletal 
tissue deformation induced fluid flow phenomenon as a technique to initiate pressure gradients 
within bone to enhance drug delivery.  
Three main mechanisms that may be responsible for enhanced drug delivery to bone 
tumors by mechanical loading are: 1) deformation of bone tissue creates pressure differences that 
drive fluid flow within bone and within the marrow cavity. These flow streams might create 
interstitial fluid currents towards the tumor and improve convective delivery; 2) formation of 
hydrostatic pressure within the marrow cavity could overcome the high pressure within the 
tumor, creating radial flow towards the tumor center; and 3) mechanical loading could deform 
blood vessels near the tumor and create increased fluid filtration. Implementing load-bearing 
activity may be a simple, efficacious approach to enhance drug delivery to bone tumors, thereby 
decreasing unwanted side effects and increasing a patient’s quality of life. 
 
1.2 Physiological hallmarks of solid tumors 
1.2.1 From normal to malignancy: There are more than 100 distinct types of cancer, and 
histological subtypes of tumors can be found within affected organs (Hanahan and Weinberg, 
2000). Therefore, understanding how tumors develop and behave can provide valuable 
information on how to target them and therefore enhance drug efficacy. This broad spectrum of 
tumors shows that cancers have common and uncommon occurring physiological hallmarks. 
Some common physiological hallmarks of solid tumors include self sufficiency in growth 
signals, insensitivity to anti-growth signals, insensitivity to apoptosis signals, increased 
replication potential, persistent angiogenesis, and tissue invasion and metastases. Some 
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uncommon physiological hallmarks in cancer include DNA damage/replication stress, 
proteotoxic stress, metabolic stress, and oxidative stress (Luo et al., 2009).  
 
1.2.2 Acquired autocrine signaling: Acquired autocrine stimulation and cell membrane 
receptor over-formation, driven by dominant oncogene over-expression, allows cancer cells to 
reduce their dependency on their environment (Hanahan and Weinberg, 2000). Nonetheless, 
tumors are composed of several cell types, such as stromal cells, fibroblasts, and endothelial 
cells, which play key roles in tumor growth, stimulation and proliferation (Sheih, 2011).  
 
1.2.3 Anti-growth signal insensitivity: It is known that healthy cells differentiate and 
proliferate until they reach a state of homeostasis. However, disruption of the pRb 
(retinoblastoma protein) signaling pathway, the pathway where almost all anti-proliferative 
signals end up, stimulates cancer cells to change from the normal state of homeostasis to become 
antigrowth-signal insensitive (Weinberg, 1995). There are different ways to disrupt the pRb 
signaling pathway, including overstimulation by extrinsic factors (Zuscik et al., 1995) and by 
pRb hyper-phosphorylation (Lee et al., 1992). Disruption of the intrinsic transcription factors 
E2F-pRb complex results in enhanced cell proliferation by enhanced cell division activation 
(Chellappan et al., 1991). Furthermore, complete deregulation of the pRb pathway can be caused 
by several pRb-gene mutations.  
 
1.2.4 Inactivation of tumor suppressor; preventing apoptosis: A tumor’s capability to 
expand is explained by the prevalence of a positive net cell number, the total number of cells 
minus dead cells. Apoptosis is driven by intracellular and membrane bound signaling factors that 
regulate cell death and survival, maintaining tissue stasis (Hanahan and Weinberg, 2000). 
Inactivation of apoptotic soluble signals is explained by the inactivation of tumor suppressor 
genes such as p53 (caspases machinery), where p53-deficient mice develop normally but are 
susceptible to spontaneous tumors (Donehower et al., 1992). Enhancement of oncogene 
expression like myc provokes enhancement of cell division and reduction of cell apoptosis 
(Khaira et al., 1998).  Enhancement of the myc gene was seen in Khaira et al. (1998), where 
amplified translocated c-myc genes were present in lymphoma cell lines. Moreover, hyper-
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activation of membrane bound protein blc-2 blocked cytochrome C release from mitochondria 
therefore preventing apoptosis (Yang et al., 1997). 
 
1.2.5 Increased replication potential; immortality: Immortality, or lack of senescence, is 
a classic hallmark of cancer cells.  Telomeres, the ends of chromosomes, are maintained in 
cancer cells, avoiding chromosomal condensation (fusion) and therefore cell apoptosis, in 
contrast to healthy cells (Rudolph et al., 1999). There is no telomeric-length developmental 
dependence in mice; however, there is a telomeric-length effect on life span, healing power and 
hematopoiesis (Rudolph et al., 1999).  Up-regulation of telomeric repair enzymes (telomerase) 
permits unlimited replication (mitosis) of the next generation’s cancer cells in contrast to 
telomerase-deficient mice cells (Collado et al., 2007). Consequently, tumors never grow old. 
     
1.2.6 Sustained angiogenesis and invasion leads to metastases: Driven by the concept of 
diffusion, a cell must be located ~100µm from the blood supply to survive. This allows the cell 
to obtain sufficient oxygen, nutrition, and an outlet for waste, thus maintaining normal stasis. It 
has been shown in a mouse model that in order for cancer cells to continue proliferation, 
angiogenesis becomes a vital acquired trait for further tumor growth and development 
(Hashizume et al., 2010) (Fig. 1). Mice that received inhibitor for Ang2 and VEGF (angiopoietin 
and vascular endothelial growth factors, respectively) presented reduced vascular sprouts and 
reduced tumor vascularity and growth, in addition to increased cell death. A tumor’s angiogenic 
ability might be caused by abnormal environmental changes, such as necrosis (e.g., lesions or 
fracture in normal tissue) or by genetic set-points driven by growth/expansion and cell 
differentiation (Shieh, 2011). In cancer, physical stresses and genetic predispositions offsets the 
production of pro and/or con signals for angiogenesis. In any case, increased expression of 
VEGF and/or FGFs (fibroblast growth factors), or inhibition of thrombospondin-1 and/ or B-
interferon offers the tumors the ability to grow blood vessels, expand and acquire new 




Figure 1. The process of 
angiogenesis is a series of 
linked and sequential steps that 
ultimately leads to the 
development of a vascular 
blood supply to the tumor mass. 
Tumor cells or host cells 
(immune or adjacent normal 
tissue cells) secrete angiogenic 
growth factors. Cell-cell and 
cell-environment interactions 
lead to endothelial cell 
proliferation, migration, and 
invasion. Vessel formation may 
be increased by certain stimuli 
such as hypoxia, low pH, 
cytokines, activated oncogenes, 
or loss of tumor suppressor 
gene function. From Reinmuth 
et al., 2003. 
 
 
Driven perhaps by an enhanced ability to invade neighboring tissue or by the physical 
stress of the environment (matrix stiffness, nutrition levels, cell density, pH levels, necrosis), 
malignant cancer cells will eventually detach from the primary colony and move to a distant 
location. In metastases, cancer cells become absolutely independent of their environment, which 
probably indicates a reverse differentiation step to a level of higher cellular pluripotency, 
(epithelial to mesenchymal transition), therefore allowing for cancer cells to accommodate to 
new environments (Shieh, 2011). The most notable capability for detachment is the lack of 
physical cell-to-cell coupling and cell-to matrix adhesion. Deregulated adhesion molecules 
include integrins, CAMs, and cadherins (Hanahan and Weinberg, 2000). The lack of cell-
adhesion coupling is a resultant of bypassing the intracellular anti-growth signaling, which is 
downstream of the adhesion signaling pathway, or as a result of under-expression and/or over-
inhibition of these adhesion complexes (Shieh, 2011).  
There are pre-requisites for metastases, and these pre-requisites are the inclusive 
physiological hallmarks of cancer (Nguyen and Massague, 2007). Consequently, after 
proliferation, invasion, angiogenesis and lost adhesion, the sequential developmental progression 
of cancer cells will lead to dissemination and colonization.  Dissemination is explain by the 
theory of “seed and soil” of compatible tissues and/or within the concept of natural selection and 
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advantageous cell adaptability (Merlo et al., 2006).  Colonization might be a genetic 
predisposition of cancer cells to metastasize or might be a phenotypic trait gained by cancer cells 
in growth and development (Nguyen and Massague, 2007). In conclusion, transformation of 
normal cells to malignancy is a multi-step process that includes genetics, phenotypic 
transformations, common and infrequent characteristics and unknown causes, yet to be defined. 
 
1.3 Solid tumors and drug delivery  
1.3.1 Sequential changes of the tumor phenotype and the effects on drug delivery; 
cellularity and tumor density: Over 85% of tumors are solid and they share a physical phenotype. 
Solid tumors contain common characteristics that hinder drug delivery. These characteristics 
appear sequentially and are set initially by the fast proliferation and increasing cellularity of the 
tumor (increased tissue density). The large cell number per unit volume displaces existing 
vessels and creates alienated cell populations (Minchinton and Tannock, 2006). Increasing cell 
density provokes the collapse of the existing lymphatic vessels, making them non-functional 
(Shieh, 2011; Padera et al., 2004). Ultimately, continuous tumor growth will lead to the 
establishment of new blood vessels in response to acquired genetic/phenotypic traits and or in 
response to the physical stress. The new blood vessels created are asymmetric, more permeable, 
and blood flow within them is irregular (Baish et al., 1997) (Fig. 2). As tumor cellularity and 
angiogenesis increases, increased extracellular matrix (ECM) production also occurs. This 
combined disorganized growing system develops high interstitial pressure, which is a major 
factor in convective and diffusive drug delivery. 
 
Figure 2. The natural 
hierarchy of blood vessel 
formation: a) From arteries 
to arterioles to capillaries 
to venules and finally to 
veins. b) Tumor vessel 
formation is abnormal and 
irregular, blood flow is 
sometimes reversed, and 
tissue architecture is 
asymmetrical. From Jain 





1.3.2 The tumor vasculature and drug kinetics: In combination with solid tumor physical 
traits that hinder drug delivery, systemic drug pharmacokinetics is also an important factor in 
drug transport (Minchinton and Tannock, 2006). Drug delivery is characterized by dosage, 
plasma metabolism, penetration and distribution homogeneity, effective concentration per 
volume, drug specificity and mode of action, retention and clearance (Garattini, 2007). Because 
of the drug delivery kinetics, in vivo models of chemotherapy distribution measured by 
fluorescence and immuno-histochemistry have shown a heterogeneous delivery with poor uptake 
(Minchinton and Tannock, 2006) (Fig. 3 and Fig. 5). Inferior delivery and uptake has been 
correlated with increased tumor size, low time of exposure, and seclusion from blood vessels.  
Consequently, further tumor development worsens delivery and uptake of therapeutic agents, 
decreasing the drug toxicity level, therefore worsening the patient’s prognosis.  
 
 
The distribution of drugs via tumor vasculature is characterized by the transport across 
the vascular wall and then by the transport through the interstitial compartment (Baish et al., 
1997) (Fig. 3). Such transport of molecules of any size, charge and configuration must involve 
diffusion and/or convection. Drug delivery in normal and tumor tissue is strongly related to 
Fick’s law, Darcy’s law, and Starling’s law of transcapillary flow (Jain, 2001; Heldin et al., 
2004). Transport across the capillary wall is determined by 1) the hydrostatic pressure in the 
Figure 3. Schematic illustrating the gradients in oxygen, nutrients and effectiveness of drug 
concentration in a tumor. The supply of a drug to the tissue depends on its dose and pharmacokinetics. 
Movement of drug in the interstitial space is hindered by interactions with extracellular and cellular 
components. These factors add to the tortuosity and irregularity of blood vessels. Systemic drug 
delivery and tissue penetration is determined by the balance among supply, metabolism, penetration, 
binding and sequestration.  From Minchinton and Tannock, 2006. 
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capillary (systolic-diastolic pulse pressure difference), 2) colloid osmotic pressure in the 
interstitium (water content driven by the solute concentration difference), 3) the hydraulic 
conductivity of the vessel (blood vessel surface area and permeability/leakiness) and 4) the 
reflection coefficient (concentration of albumin in the plasma). In addition, the distribution of 
drugs is also defined by the vessel geometry (anisotropy, density, length and diameter), blood 
cellularity, and flow rate (viscosity), also known as Bernoulli's principle. 
Tumors are dynamic, growing systems that affect the pharmacokinetics and 
pharmacodynamics of a drug, playing an important role in the spatial and temporal drug 
distribution (Jang et al., 2003). A spherical tumor with a diameter less than 2 mm can be 
supported by existing tissue vasculature, but further growth will require angiogenesis (Zetter, 
1998). This vascular angiogenesis in animal models has been shown to sprout and fully develop 
within 10-17 days (Jang et al., 2003). Even though these vessels are formed by healthy 
endothelial cells, the fast rate of formation leads to tumor vessels that are leaky as a result of 
discontinuities in the endothelium. The spatial and temporal distribution of the blood vessels in 
the tumor is such that the veins are primarily located in the central region of the tumor, while the 
arterioles are in the periphery. This vascular arrangement can explain the results cited by 
Fukumura and Jain (2007) in which the pressure measured is high in the solid tumor center, and 
then pressure decreases as it reaches the periphery and suddenly drops once past the tumor 
border. The sudden drop of pressure can be mostly attributed to the functional lymphatics outside 
the tumor volume.   
 
1.3.3 Increased rate of extracellular matrix production; effects on drug distribution: The 
tumor blood flow and the transport into the surrounding tissue can also be affected by the over-
expression of ECM molecules, which acts as a barrier that causes drug accumulation and 
retention (Fig. 4). The ECM rate of synthesis, ECM composition, ECM architecture and tissue 
function are important factors in drug delivery (Jang et al., 2003). Drug affinity to ECM 
molecules can modify temporal and spatial drug distribution. An example of ECM involvement 
and drug distribution in tumors is the higher production of glycosaminoglycans (hyaluronan and 
proteoglycans), which lowers the hydraulic conductivity and thus the convective interstitial flow. 
Also, high production of collagen contributes to transport resistance for large molecules like IgG 
antibodies. Wiig et al. (2008) provide a great review on the distribution of macromolecules in 
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healthy and diseased tissue. Their description states that the phenomenon of interstitial exclusion 
is an obstruction of the interstitial fluid space available for macromolecules, given that two 
molecules cannot occupy the same space. These steric exclusions add to the ionic interactions 
between drugs and the ECM (Fig. 4).  
Figure 4. Schematic of the exclusion 
phenomenon in the interstitium. The 
interstitial space is divided into two 
phases: the interstitial fluid and the 
structural molecules. Steric exclusion 
results from ECM macromolecular 
crowding. Available space for other 
molecules diffusing is less, equal or 
more than the total interstitial fluid 
volume. Charge exclusion, at 
physiological pH values, can have high 
affinity for the drug being delivered. 
Shown are collagens (black and white), 
negatively charged proteoglycans (black), small drug (yellow), large drug (dark blue) and positively 
charged large drug (light blue). From Wiig et al., 2008. 
 
1.3.4 Drug delivery in tumors: There have been several approaches to enhance the 
delivery of high molecular weight compounds, antibodies, micelles, liposomes, nano-particles, 
magnetic or charged particles, and other compounds in vivo. Some approaches include 
increasing the transmural vessel pressure difference by increasing systemic blood pressure, in 
addition to regulating vasculature structure (Fukumura and Jain, 2007), enhancing vessel dilation 
and homogeneity for greater blood flow (Fukumura and Jain, 2007), implementing artificial 
lymphatics (DiResta et al., 2007), implementing ultrasound as a mechanical wave to enhance 
filtration by thermal induced sonoporation (Besic, 2007) and the use of magnetic fields to 
improve spatial localization of charged particles (Hui, 2008). 
 It is important to mention that delivery of even small molecules that are diffusion-driven 
can be enhanced by the mixing principle of applied convention. This principle allows for 
temporal improvement and enhanced spatial distribution in drug transport. 
  
1.3.5 High tumor interstitial pressure, increased ECM production and sustained 
vasculature; effects on drug delivery: An illustration of the consequence of high interstitial 
pressure and cell populations distant from the blood supply is the formation of hypoxic cells 
(Fukumura and Jain, 2007), which by definition are less affected by radiation therapy, given that 
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they lack available oxygen for production of free radicals. Because cancer cells have defective 
nucleotide repair machinery, chemotherapy targets the DNA of fast replicating cells (Ta et al., 
2009). However, hypoxic cells do not proliferate as fast as non-hypoxic cells, which make them 
less sensitive to chemotherapeutic agents. Another consequence of increased interstitial pressure 
and increased ECM production is an accumulation of metabolic products (Tannock, 2001). These 
metabolic products decrease the environmental pH, hampering the functionality of some drugs. 
The final outcome of high interstitial pressure in solid tumors is that the net convective flow is 
outward from the tumor’s center (Baxter, 1989), preventing effective drug distribution deep into 





Figure 5. Section from a mouse mammary tumor (MS-
EMT6) showing the distribution of doxorubicin (blue, 
autofluorescence) in relation to tumor blood vessels 
(red, CD31 platelet/endothelial cell adhesion molecule 
1 monoclonal antibody) and regions of hypoxia (green, 
hypoxia-selective agent EF) in vivo. Doxorubicin is 
distributed around tumor blood vessels and there is 
inability to reach deep into the interstitial space where 
more cells are located. From Minchinton and Tannock, 
2006. 
 
1.4 Human bone, the organ 
 1.4.1 Overview of the general function of bone: Bone is a dynamic system that performs 
several functions. Bone provides support and locomotion to the body, and this musculoskeletal 
capability is efficiently accomplished by a balance between bone mass and architecture 
(Confavreux, 2011). The equilibrium between bone mass and structure allows for a lightweight 
organ that is strong/flexible and tough/stiff so it is capable of sustaining mechanical strains 
without fracture (Ritchie, 2010). Moreover, bone also provides protection and shelter to soft 
organs, such as the lungs and marrow (Confavreux, 2011). Furthermore, bone is a storage and 
exchange house for minerals such as calcium, phosphate and magnesium, which are essential for 




1.4.2 Bone development, adaptation  and morphology: The adult human body consists of 
about 216 bones and every bone begins from mesenchymal condensation at embryonic 
development (Bartl and Frisch, 2009). Mesenchymal condensation allows for bone formation 
either by intramembranous ossification or endochondral ossification (Jee, 2001). 
Intramembranous ossification produces bones such as the skull, facial bones and mandible, 
whereas endochondral ossification produces bones such as the vertebra, tibia, femur and pelvis.   
Intramembranous ossification is characterized by a fibrous membrane, where primary 
spongiosa (the first cancellous bone) is laid down. The primary spongiosa is finally remodeled 
by a vascular system. Endochondral ossification is distinguished from intramembranous 
ossification by cartilaginous deposits that mature and calcify. The calcified cartilage sets the 
ground for osteoblastic deposition of osteoid then to become woven bone (Majeska, 2001; Jee, 
2001). The radial expansion of osteoid and woven bone creates the foundation for cortical-bone 
that is replaced with primary lamellar bone and eventually by vascular canals with secondary 
lamellar bone. Longitudinal expansion of this embryonic osteoid-woven bone leads to formation 
of spicules that will become trabecular bone, which eventually get remodeled to trabecular-
lamellar bone (see Fig. 9 for illustration of trabecular and cortical bone).  
Bone takes its shape and adapts by two processes, modeling and remodeling, respectively 
(Fig. 6). Modeling is a developmental condition where bone surface/volume formation and 
resorption drifts generate the bone’s anatomical/mechanical shape. Further into maturity, bone 
remodeling takes over as a process of tissue maintenance and mechanical augmentation. 
Remodeling serves to replace mechanically incompetent bone, dead bone and fractured bone and 
serves to adapt bone to mechanical stimuli.    
 
Figure 6.  Diagram illustrates 
the relationship between 
strains (µstrain) and the 
adaptive responses of a 
mechanosensory system. 
Minimum effective strains 
(MES) are defined by 
thresholds (physiological set 
points) where bone mass 
adjusts to strain/stress. 
r=remodeling, m= modeling, 
p= pathologic, Fx= fracture 




As stated, the groundwork-material of mechanically functional bone is the osteoid. 
Osteoid is primarily formed as non-calcified collagen (mainly Type I, with traces of type II, III, 
V and X), and non-collagenous protein (glycoproteins, glycosaminoglycans, RGD containing 
proteins, and serum proteins) (Jee, 2001; Majeska, 2001; Robey & Boskey, 2008). Post 
translational/post transcriptional modifications and manufactured quantities of these proteins are 
genetically set (Majeska, 2001; Zuscik et al., 1995) and they define the tissue quality (Viguet-
Carrin et al., 2006) (see Fig. 7(A) for hierarchical structural organization of bone and collagen). 
Successively, ionic mineral condensation, mainly calcium and phosphate, occur after osteoid 
deposition. Alkaline phosphate and the non-collagenous proteins produced by osteoblasts may 
regulate crystal formation (Boskey, 2001). These mineralization regulating factors, also called 
nucleators, control the size, shape and composition of the crystal (Robey & Boskey, 2008) (Fig. 

















Figure 7. Hierarchical structural organization of bone. 
A) Cortical and cancellous and are considered 
macrostructures, osteons (Haversian system) are 
considered  microstructures, lamellar bone (primary and 
secondary) is considered a microstructure and collagen 
fibers, mineral crystals and non-collagenous proteins are 
considered nano structures. B) Further description of 
collagen fibrils, fibers and bone mineral crystals. Shown 
here is the 67 nm periodic pattern resultant from the 
presence of gap (40 nm) and overlap (27 nm) regions of 
the assembled collagen molecules. C) Such gap and 
overlaps can be seen in a TEM micrograph of a 
mineralized collagen fibril.  Top images from Rho et al., 






Because of temporal and spatial differences in the tissue mineralization, human bone 
contains heterogeneous bone mineral density distribution (BMDd) cross-sectionally and 
















Figure 8. A) X-ray image of a proximal femur with its corresponding ex-vivo specimen. Delineation of 
cortical and cancellous bone and marrow is shown. Lighter color bone on the x-ray is represented as 
higher attenuation value (cortical and trabecular) compared to marrow, which is represented by low 
attenuation values (dark color). B) Backscattered electron image of trabecular and C) cortical bone. The 
surface of trabecular bone features packets of different grey-levels, which result from a heterogeneous 
bone mineral density distribution. The numbers indicate the average mineral content within bone packets. 
The bone packet with the lowest mineral content corresponds to fresh bone formation, whereas higher 
numbers correspond to time points with more mature mineralization. Similarly we can see  the 
mineralization heterogeneity between the different bone structural units due to the Haversian bone 
remodeling activity in cortical bone. Top images from Downey and Siegel 2006 (A); bottom images from 
Fratzl et al., 2004 (B); Bala et al., 2010 (C). 
 
Bone develops into a more mature and more mechanically efficient organ when woven 
bone is replaced by a more organized structure, lamellar bone. Cortical lamellar bone is 
collection of 3- to 7-µm-thick layers that run primarily parallel to the longitudinal axis of the 
bone. Lamellar bone is more structured and is superior mechanically to woven bone. Lamellar 
bone has well-organized collagen fiber arrangement and orientation (Viguet-Carrin et al., 2006).  





Cortical section Trabecular strut C B 
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with that of the major input load (Rho et al., 1998). The composite nature of lamellae bone 
provides bone with tougher mechanical characteristics, allowing bone to hamper fracture 
expansion of micro-cracks and diffuse damage (Ritchie, 2010). Lamellar bone is also found in 
trabecular bone, and it is believed that the material quality is as efficient as in cortical bone. 
Lamellar bone is eventually adapted to be more competent mechanically and physiologically by 
remodeling with incorporation of osteons, consider being the bone structural unit of human bone 
(Bartl and Frisch, 2009). Osteons are ~200-250µm in diameter and have blood vessels, 
lymphatics and nerves running through them. The replacement of primary lamellar bone by 
osteons is orchestrated by the osteoclast-osteoblast coupled mechanism.  
 
After adolescence, bone is 65-70% mineral and 30-35% 
protein plus water and has a well defined nanostructure, 
microstructure and macrostructure (Fig. 7). Major bone structures 
are the diaphysis (bone mid-shaft), metaphysis (below growth plate 
region) and epiphysis (above growth plate region), periosteum 
(outer shell) and endosteum (inner shell), cortical and trabecular 
bone (Fig. 9). Bone marrow and cortical and trabecular vasculature 





 Figure 9. Anatomical diagram of a long bone illustrating the main bone 
regions such as the epiphysis, metaphysis, diaphysis, and cortical and 
trabecular bone. Open and fused growth plates are also shown, along 




































Figure 10. A) a schematic diagram 
of the vascular arrangement in the 
diaphysial region of a long bone; 
Depiction of the nutrient artery, 
nutrient vein, proximal and distal 
bifurcation are seen. B) The 
arterial tree in the bone marrow 
space will eventually turn into 
sinusoids and the capillary bed in 
the cortical section of the bone. The 
radial branches of the nutrient 
artery form a leash of arterioles 
that penetrate the endosteal surface 




1.5 Bone cells 
 
1.5.1 Bone cells and their lineage: Bone cells come from pluripotent stem cells located in 
the bone marrow. Mononuclear phagocytic hematopoietic stem cells give rise to osteoclasts, 
while osteoblasts are derived from mesynchymal stem cells (Krause et al., 2009; Ross, 2008) 





Figure 12.  Multinucleated osteoclasts resorbing bone to 
form resorption pits known as Howship’s lacunae. From 
Clarke, 2008. 
Osteocytes get buried into the bone matrix and lining cells are quiescent and disperse in the bone 












Figure 11. Bone cell lineage.  The osteoclasts are derived from cells in the mononuclear phagocyte 
lineage. Osteoblasts are derived from the hematopoietic stem lineage. Osteoblasts sub-divide into 
categories: 1) the osteoblasts themselves, 2) bone lining cells, and 3) osteocytes. Bone lining cells are 
basically inactive osteoblasts (not shown) that cover bone surfaces. Osteocytes are osteoblasts that have 
become encased in bone matrix during bone tissue production. From Ralston, 2009. 
1.5.2 Osteoclasts are known as the demolition cells of bone (Fig. 12). These cells have an 
approximate diameter of ~100µm in the fully multiple-nucleated form. Fully differentiated 
osteoclasts attach to bone surfaces and perform resorptive activity. (Bartl and  Frisch, 2009). 
Osteoclasts secrete protons, ions and matrix metalloproteinase (MMPs) to demineralize the tissue 
and degrade protein. Major regulating 
factors of osteoclast activity are PTH, 
prostaglandin and vitamin D, which are 
osteoblast-osteoclast OPG-Rank 
signaling stimulators (Zuscik et al., 
1995; Ross, 2008). Inhibitors of 
osteoclasts activity include calcitonin, 




Figure 13.  Osteoblasts synthesizing 
proteinaceous matrix, composed mostly of 
type I collagen, to fill in resorption pits. The 
proteinaceous matrix is gradually 
mineralized to form new bone. From Clarke, 
2008. 
 
1.5.3 Osteoblasts are bone forming cells 
(Fig. 13) because they produce the groundwork-
material of mechanically functional bone, the 
osteoid. Osteoblasts are ~15-30µm in diameter 
and work on preexisting surfaces that have been 
previously created either by chondrocytes (in 
formation of bone in developmental phase), or 
by osteoclasts (formation of bone in remodeling) 
(Bartl and  Frisch, 2009). It is known that after 
osteoblasts finish bone formation, they undergo 
apoptosis, or they become osteocytes or bone 
lining cells. Osteocytes, osteoblast and bone 
lining cells are connected through gap junctions 
and communicate to regulate bone function 
(Clarke, 2008). Major activating factors of osteoblasts are morphogenic proteins (BMPs) and 
stimulating growth factors (IGFs, TGFs and FGFs) (Zuscik et al., 1995; Krause et al., 2009).  
 
1.5.4 Osteocytes are matrix-embedded osteoblasts 
(Franz-Odendaal et al., 2006) (Fig. 14). Osteocytes are a 
network of cells interconnected by gap junctions. It is 
believed that osteocytes control the efflux of mineral in 
an orchestrated manner with help of osteoclasts and 
bone lining cells (Bonewald and Johnson, 2008). 
Osteocytes also detect and might repair microcracks. 
Given to their advantageous distribution within bone, 
osteocytes are believe to be the mechanical transducers 
of bone (Franz-Odendaal et al., 2006) (Fig. 15), and they 
are believed to control bone formation by regulation of 
inhibiting factors such as sclerostin (Robling et al., 
2008).  
Figure 14. Bone slice injected in vivo 
with reactive red (∼1-nm diameter). 
Staining shows vascular pore, osteocyte 










Figure 15.  Mechanical 
loading hierarchy starting 
at the whole bone organ 
and then transmitted 
through the bone tissue 
down to the cellular level. 
The mechanical forces 
stimulate osteocytes, 
which react by inhibition 
or enhancement of tissue 
turnover.  From Fritton 
and Weinbaum, 2009. 
 
 
1.6 Bone remodeling 
 
 Osteoclasts and osteoblasts play a major role in bone formation and adaptation. The bone 
building unit (Fig. 16) also known as osteoclast-osteoblast cell coupled mechanism, completes 
the formation of osteons (Bartl and Frisch, 2009) and maintains bone quality. 
 
 
Figure 16.  Bone 
remodeling building unit. 
Depiction of the 
resorption and forming 
cone phases are present.  
Osteoclasts and 
osteoblasts are the main 
players. Blood vessels, 
which bring the nutrients 
and precursors of bone 
cells, are formed 
simultaneously. At the end 
of the resorption and 
forming cone, there is 
lamellar bone formation, 
a Haversian vascular unit 
and osteocytes present.  






1.7 Bone porosity, permeability, and interstitial fluid flow  
 
Bone is a porous saturated solid material. The porous-elastic behavior of bone provides 
the means for interstitial fluid flow caused by mechanical tissue strains. The mechanical loading 
deformations define the convective transport behavior of large molecules within bone. When 
mechanical loads are applied to bone, for example during walking, fluid pressure gradients are 
produced in the connected bone pores, creating interstitial fluid displacement. This load-induced 
fluid flow enhances mass transport in healthy bone and ensures the metabolic function of bone 
cells that is crucial for bone maintenance (Fritton and Weinbaum, 2009). Interstitial fluid 
pathways in bone have been quantified using vascular injection of molecular tracers (Knothe-
Tate et al., 1998; Wang et al., 2004; Ciani et al., 2005).  Investigators have also used tracer 
methods to experimentally confirm the existence of load-induced transport within bone 
tissue; applying mechanical loading to animal limbs has demonstrated an enhanced delivery of 
tracer molecules through the bone tissue (Knothe-Tate et al., 2000; Tami et al., 2003). The 
interstitial fluid flow is related to the bone permeability and therefore to the bone porosity. 
Porosity in bone can be defined as follows 1) the space occupied by the lacunar- 
canalicular network, 2) the space occupied by the vascular system, 3) the collagen-apatite 
porosity, and 4) the space between the trabecular plates and struts. The collagen-apatite porosity 
is not connected and is extremely small (~10nm); the water is considered bound to the surfaces, 
therefore having no effect on the interstitial fluid flow (Gailani et al., 2009). The trabecular bone 
porosity contains the greatest porosity range and it is profoundly defined by the porosity 
orientation and anatomical location. Fluid flow in trabecular bone occurs when marrow moves 
around the plates and struts. Lacunar-canalicular fluid flow occurs when interstitial fluid (mainly 
water and ions) moves between the osteocyte body and the lacuna wall and between the cell 
process and the canaliculi wall. This flow in the lacunar-canalicular system is an important 
predictor of cellular communication and mass transport (Knothe Tate et al., 2004).   
Several studies on the values of porosity and permeability report vascular porosity 
















; a trabecular porosity ranging from 0.1 to 0.95, and a trabecular 
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 (Cowin, 1999; Cowin, 2010; Gardinier et 







Figure 17. Sketch showing cross 
section of an osteon. Four 
features are depicted: 1) the 
osteonal canal porosity including 
a blood vessel, 2) the lacunae 
and the canalicular  porosity, 3) 
the material in the space between 
the lacunar–canalicular porosity 
contains the collagen–apatite 
porosity, and 4) cement line. 
From Cowin, 2001. Trabecular 
porosity can be seen in Figs. 8 
and 9. 
 
1.8 Overview of bone cancer  
1.8.1 Primary bone cancer: Primary tumors arise from the tissue/organ where they are 
located and can be classified either as benign or malignant (cancer). Primary tumors start as 
benign and might transform into malignant cancers. Primary malignant tumors arising in the 
skeletal system are rare, representing just 0.001% of all new cancers (Malawer et al., 2005).  
According to the Surveillance Epidemiology and End Results (SEER) cancer statistics review 
(CSR) from the National Institutes of Health (NIH), in the United States 1.0 per 100,000 men 
and 0.8 per 100,000 women will be diagnosed with some type of bone or joint-related cancer. 
Furthermore, 0.5 per 100,000 men and 0.4 per 100,000 women will die of this disease.  
The main types of primary cancers to bone include osteosarcoma (predominately produce 
osteoid) (Fig. 18) and Ewing's sarcoma (Malawer et al., 2005). These primary bone cancers are 
rare, and are considered the cancer of the young; patients are usually between ages 10 and 25. 
There exist cartilage-forming tumors in bone, such as osteochondroma, enchondroma, and 
chondrosarcoma, which can be intramedullary or peripheral. Also, osteoid forming tumors are 











1.8.2 Secondary bone cancer; metastasis to bone:  Secondary tumors are malignant 
cancer cells that originally developed in a distant organ/tissue from where they detached. These 
tumors develop genotypic and phenotypic characteristics that are similar to the tissue from where 
they came from and acquire traits from the environment where they metastasized. Metastases can 
happen at any age; however, metastases to bone are more frequent than primary bone tumors and 
usually affect older people (Manoso and Healey, 2005). Cancers that preferentially metastasize 
to bone are breast, kidney, lung, prostate and thyroid (Manoso and Healey, 2005).   
 
1.8.3 Staging and classification of bone tumors: Classification of bone tumors can be 
given by the rate of cell growth, subsequent progression, degree of invasion and whether 
metastasis has occurred (Malawer et al., 2005; Lichtenstein, 1951). Tumor presence in bone can 
also be classified by anatomic location and border pattern. Benign lesions present well-defined 
borders in contrast to transitional borders, which are more aggressive, faster-growing tumors 
indicative of malignancy. Bone destruction is a strong predictor of tumor aggressiveness, in 
contrast to matrix formation, where malignancy cannot be predicted by its presence 
(Lichtenstein, 1951). Finally, a bone tumor can be staged by its histological involvement and 
lymph node involvement.  
 
Figure 18. A) Inverse magnetic resonance 
imaging demonstrating the intramedullary 
extension of osteosarcoma in human proximal 
tibia. B) X-ray radiograph marks sclerosis of 
osteosarcoma of the distal femur. Damage can 
be seen within the intramedullary canal and a 
posterior extraosseous component that shows 




1.8.4 Effects of tumor growth in bone: Bone tumor growth in itself is associated with 
compromised hematopoiesis, lack of erythrocyte and platelet creation, compromised leukocyte 
production, metabolic disorders such as hypercalcemia, which can occur in patients with 
extensive metastatic disease, spinal cord compression (Koutsilieris, 1995) and pain and 
immobilization. The last two symptoms largely contribute to the diminishment of a patient’s life 
quality. The destruction of the bone architecture is caused predominantly by stimulated bone 
cells and this process is independent of the tumor growth. Involvement of cancer cells in bone 
destruction is indicative of higher degree of malignancy (Manoso and Healey, 2005). Bone 
tumors provoke three general types of lesions: sclerotic, lytic and mixed (see Fig. 18 for details) 
(Vassiliou et al., 2007). These lesions are characterized by osteoblast-dependent and/or 
osteoclast-dependent mechanisms stimulated by over-expression of growth factors.  
 
1.8.5 Evaluation, side effects and treatments against bone cancer; emphasis on 
bisphosphonates, the drug and tracer: Radiographic evaluation, combined with the clinical 
history and histological examination, is necessary for accurate diagnosis of bone cancer. Bone 
scans, angiography, CT, and MRI are generally not helpful in determining a diagnosis but are 
important in delineating the extent of local involvement (Malawer et al., 2005).  
Primary and metastatic bone tumors are treated using chemotherapy, and adequate drug 
delivery is required for significant therapeutic effect. In some cases chemotherapy is used to 
reduce the size of the tumor before surgery; otherwise it is used to treat the underlying disease. 
Some chemotherapeutic drugs used to treat sarcoma include doxorubicin, ifosfamide, etoposide, 
cisplatin and methotrexate (Ta et al., 2009). Cancer patients going through chemotherapy also 
receive an antiemetic regimen to decreased side effects such as vomiting, incontinence, fever and 
skin sensitivity. However, more serious side effects include anemia, transient elevation in 
bilirubin, peripheral neuropathy, hearing loss, electrolyte disturbances such as hypomagnesemia, 
hypocalcemia, and hypokalemia, heart failure, somnolence, hallucinations and others (Berger 
and Clark-Snow, 2005; Weiss, 2005). Chemotherapy is administrated intravenously or orally. 
Treatment can take several hours, while prescribed regimes might be spread within a few days, 
weeks or months (Spira and Ettinger, 2002). Adjunct treatments to chemotherapy can include 
hormonal therapy, anti-angiogenic drugs, genetic therapy and others.    
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 Surgery and radiotherapy are also common treatments in bone cancer. Metastatic bone 
cancer may require the addition of hormonal therapy, immunotherapy, and bisphosphonate 
therapy (Manoso and Healey, 2005).  
Bisphosphonates are analogues of pyrophosphate (Phosphorous-Oxygen-Phosphorous (P-
O-P)), and they have important anti-resorptive properties in bone (Roelofs et al., 2006). 
Bisphosphonates are used to treat metabolic diseases such as cancer-induced bone osteolysis, 
osteoporosis and hypercalcemia. Bisphosphonate long-term action in the body is based on the 
principle of lack of enzymatic degradation (Malawer et al., 2005). Non-enzymatic degradation 
provides bisphosphonates with long half-lives (decades). Different bisphosphonates exist, but the 
most efficient/stronger acting ones are those that contain nitrogen in their chemical structure 
(Russell, 2007).  The phosphate groups within bisphosphonates allow them to attach to 
hydroxyapatite crystal (Russell, 2007), creating efficient bone uptake and retention. At the 
cellular level, bisphosphonates interfere with the mevalonate pathway by inhibiting farnesyl 
pyrophosphate within cells, leading to cell death (Roelofs et al., 2006). Not only are osteoclasts 
affected by bisphosphonates, but also osteocytes become hyperactive and lymphocytes 
proliferate in vivo (Bukowske et al., 2005). Such effects might explain the effects of 
bisphosphonates in tumor burden.  
The bisphosphonate pamidronate has been shown in several studies to be effective in 
treating osteolytic disease (Manoso and Healey, 2005). Pamidronate is an intravenous-delivered 
bisphosphonate (Gatti and Adami, 1999) used not only to prevent progression of the bone 
destruction but also to palliate pain.  Pamidronate retention in patients with breast cancer 
metastasized to bone (infused monthly) is highly variable but the uptake is large, and its anti-
resorptive effects are dependent on previous treatments (Cremers et al., 2005).   
 
1.9 Animal models of bone cancer  
 1.9.1 Bone metastases models: To allow for a better understanding of the biological 
complexity that characterizes metastases, in vivo animal models are required, given that in vitro 
models cannot always provide enough data (Khanna and Hunter, 2005) such as a inclusion of a 
vascular system and high interstitial pressure. In cancer research, in vivo models of bone 
metastasis with human cells consist of injections/inoculation of cancer cells orthotopically, intra-
cardially/arterially, intravenously (via the tail vein), directly intra-osseous (intrafemoral and 
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intratibial) and xenograft transplantation into immuno-compromised hosts (Degraff et al., 2009; 
Blouin et al., 2005) like mice or rats. Even though the early steps of metastases cascade is 
overlooked/eliminated in some animal models (escape of primary tumor, embolism, invasion of 
new tissue and extravasation (Khanna and Hunter, 2005)) such as transplantation and injection, 
the histo-pathological phenotype is reproduced, and the bone-cancer cell interaction can be 
quantified (Degraff et al., 2009). It is important to keep in mind the effect of the lesion caused by 
the injection and inoculation of cells; it is important to validate and interpret the physiological 
response (Blouin et al., 2005). There exist spontaneous murine models of cancer such as lung, 
breast, prostate, and kidney, but the probability of metastases to bone is rare or null (Degraff et 
al., 2009; Blouin et al., 2005). Genetic changes to the animals increase the probability of 
spontaneous cancer that metastasizes to bone; however, genetically modified mice or rats might 
not represent the human body as well as a syngeneic cancer model (Degraff et al., 2009). For 
example, nude mice that have T cell depletion have impaired angiogenesis (Khanna and Hunter, 
2005). Syngeneic cancer models allow for the use of immuno-competent animals with cancerous 
cell lines of the same species; therefore a better representation of cancer-host interaction can be 
achieved (Khanna and Hunter, 2005). 
  
1.9.2 Walker 256 cancer cells; from breast to bone: The selectivity of cancer cells to 
metastasize to bone is due to the rich growth factor environment that acts as a chemo-attractant 
and because of expression of selective adhesion molecule (Blouin et al., 2005). In breast cancer, 
Walker 256 (W256) cancer cells were discovered in the mammary gland of a 10-month-old 
albino rat (Blouin et al., 2005). W256 are considered carcinoma and sarcoma because of the 
presence of several cell types in the tumor mass. W256 do not express estrogen receptors (Blouin 
et al., 2005), but produce parathyroid hormone-related protein PTHrP. Intra-arterial injection of 
W256 cancer cells that metastasize to bone provoke bone destruction as fast as in 7 days in rats 
(Degraff et al., 2009). Intratibial injection of W256 cancer cells in rats provoke bone 
deterioration detectable by day 20, which included medullary bone loss and full thickness 
unicortical and/or bicortical bone loss. (Mao-Ying et al., 2006). Morphologically, W256 are 
large, contain an oval shaped nucleus, have a high nucleus to cytoplasm ratio, contain smooth 
membranes but with microvilli and have a dense rough endoplasmic reticulum. Immuno-
histochemistry analysis indicates that W256 are derived from primitive hematopoetic stem cells 
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(Simpkins et al., 1991). W256 produce matrix metalloproteinases such as MMP9 (Pavlaki et al., 
2009 and they have been proof sensitive to cisplatin and chlorambucil in vitro (Simpkins et al., 
1991). 
 
1.10 Imaging technology in bone cancer 
1.10.1 Radiography and computed tomography (CT): In the clinic CT and radiography 
utilize the principle of x-ray beam attenuation of the electromagnetic wave passing through a 
specimen (Kalogeropoulou et al., 2009) to image for tissue abnormalities. The degree of 
attenuation is mainly determined by the density and thickness of the specimen. Dense materials, 
such as the calcium crystal in bone, attenuate the x-ray beam, whereas, marrow and blood have 
less attenuation.  A thick tissue attenuates an x-ray beam more than a thinner tissue of the same 
type. Accordingly, the tumor effects in the bone architecture can be delineated by x-ray. 
Radiography is commonly used in the clinic. It is inexpensive and fast; however, CT is rapidly 
becoming the first examination because of its 3D capabilities (Malawer et al., 2005). In research, 
CT has been used to quantify structural damage (changes in bone volume fraction) and its 
relation to bone fracture (trabecular and cortical thickness and shape) (Nazarian et al., 2008; 
Hildebrand et al., 1999). In the clinic, simple correlations have been used to identify fracture risk 
in patients with bone cancer as well as osteoporosis (low bone mass implies higher risk of 
fracture). Animal models of bone cancer and high resolution microCT have been used to 
correlate bone destruction levels to 2D densitometry measurements, and the risk of fracture 
(Kurth et al., 2001). Standard density measurements such as simple radiographs do not predict 
fracture as described my micro-CT.    
Bone radiographs in cancer remain a vital element in characterizing many bone lesions 
by demonstrating abnormal physical characteristics such as calcified cartilaginous or osseous 
matrix within a bone (Manoso and Healey, 2005). The x-ray morphogenic patterns seen in bone 
cancer: osteolytic, osteoblastic, and mixed are the characteristics in radiography 
(Kalogeropoulou et al., 2009). In cancer, a trend between x-ray lesion type and origin of 
metastasis to bone has been seen such that in prostate carcinoma lesions tend to be of blastic 
appearance, whereas breast carcinomas are predominantly mixed or lytic. Lung, thyroid, and 
renal carcinoma usually appear purely lytic (Manoso and Healey, 2005).  
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CT has become useful for the three-dimensional evaluation of bone integrity and because 
of its improved spatial resolutions and easier discrimination of the soft tissue component. Also, 
CT can provide a basis for computer aided design (CAD) models for mechanical-competence 
analysis such as finite element (FE) modeling (Kalogeropoulou et al., 2009). However, CT has 
its limitations, such as it delivers substantial doses of ionizing radiation to the tissue compared to 
plain radiography. 
 
1.10.2 Single photon emission computed tomography (SPECT) and positron emission 
tomography (PET): Nuclear medicine (NM) is an example of a functional imaging modality, 
where abnormal biological and physiology activities can be discriminated from normal activities 
(Hicks, 2005).  The two main imaging modalities used in NM are SPECT (Beekman and Van der 
Have, 2007) and PET (Zanzonico, 2004). In SPECT, the radioactive detector is sensitive to 
individual gamma rays, and focusing is done with a lead collimator; however, its spatial 
discrimination is relatively poor (Beekman and Van der Have, 2007). PET works in a similar 
manner to SPECT; it uses a ring of scintillation detectors sensitive to photons that are attached to 
photomultipliers that allow for co-registration of paired annihilation events (Zanzonico, 2004).  
NM imaging involves administration of a radioactive tracer and non-invasive detection of its 
distribution within the body (Malawer et al., 2005; Manoso and Healey, 2005). The distribution 
of the drug may be related to the pharmacodynamics, and is generally also affected by “non-
specific” factors as blood flow/perfusion, vascular permeability, rates of excretion and 
metabolism, binding and others. Tracers used in SPECT are 
99m












(Hicks, 2005). In bone, SPECT technetium scans rely on the incorporation of tagged 
bisphosphonates. Bisphosphonates bind to exposed hydroxyapatite crystals. Nevertheless, bone 
scans are not specific, nor do they provide structural detail of the bone. Plain radiography, CT or 
MRI are required in NM to evaluate benign and malignant lesions and improve spatial resolution 





Chapter 2 Preliminary Study to Assess Enhancement of Drug Uptake 
Due to Mechanical Loading 
2.1 Introduction, hypothesis and aim 
Primary and metastatic bone tumors are treated using chemotherapy, hormonal therapy, 
immunotherapy, and bisphosphonate therapy, and adequate drug delivery is required for 
significant therapeutic effect. To obtain more effective drug delivery, this project investigated the 
efficacy of applying non-invasive physiological mechanical loading to enhance uptake of 
bisphosphonates to bone tumors. The investigation used a rat Walker 256 (W256) tibial tumor 
model and 
99m
Tc-labeled pamidronate as the tracer quantified using gamma camera scans. We 
considered the following hypothesis and aim: 
Hypothesis: Non-invasive physiological mechanical loading increases drug delivery to 
bone tumors.  
 Aim: To quantify 
99m
Tc-labeled pamidronate uptake into rat bone tumors after non-
invasive mechanical load application using a previously developed non-invasive tibia loading 




2.2.1 Summary of approach: W256 rat mammary carcinoma cancer cells were cultured in 
sterile conditions prior to cell inoculation. The W256 cancer cells were injected into the rat tibia 
as a model of bone metastasis, which produces predominately osteolytic bone tumors.  Tumor 
confirmation was completed 21 days after surgery with in vivo microCT. Tail vein injection of 
99m
Tc-labeled pamidronate was performed, followed by mechanical loading of tumor-bearing 
tibia using a non-invasive loading system that provides a precise, controlled loading magnitude 
and frequency (load input, displacement-controlled system).  The delivery of 
99m
Tc-labeled 
pamidronate to bone tumors was assessed using gamma camera scans (Table 1).  Controls were 







Chronological outline of experiments 
Table 1. Time line of experiments.  
 
2.2.2 Cell culturing: W256 cells were obtained from ATCC (CCL-38™, LLC-WRC 256) 
with a cell concentration of 1.0M W256 cells per ml. Cells were plated on a t75 flask (75 cm
2
) 
and incubated at 95% humidity, 5% CO2 and 37 Cº. Fresh media (M-199 powder, Sigma 
Aldrich) was prepared according to ATCC recommendations. 94% media, 5% horse serum and 
1% antibiotic (Penicillin-Streptomycin Solution, Sigma Aldrich) was used with a 7.3 pH level. 
Media contained Earle′s balanced salts and L-glutamine; sodium bicarbonate was added after 
dilution with sterile water. Cells were fed every two to three days. To obtain an adequate number 
of cells, cells were passaged only two times to prevent cellular modification. Passages were 
performed using the trypsinizing standard method followed by centrifugation, cell counting and 
re-plating. 
2.2.3 Establishment of bone tumors by injection of cancer cells: All animal protocols 
were approved by the Institutional Animal Care and Use Committee at Memorial Sloan- 
Kettering Cancer Center. 11-week-old female Sprague Dawley rats (n=12, 250g ± 27g) were 
obtained from Charles River (Wilmington, MA) and allowed to acclimate for one week, so that 
rats were 12 weeks old at the time of intratibial injections.  To insert cancer cells into the tibia, 
the rats were anaesthetized using 3%-4% isoflurane plus 20% oxygen administered using a 
precision vaporizer induction chamber. Using a nose cone, anesthesia was maintained using 1%-
1.5% isoflurane plus 20% oxygen. The right knee was shaved and cleaned with povidone-iodine 
solution and 70% ethanol pads.  The tibia was  exposed with an incision (approximately 5 mm) 
made along the patellar ligament, and a 28G needle was used to inject 2.5M W256 cells/ 25µL.  
The 28G needle was inserted through the periosteum into the metaphysis about 7 mm below the 
knee joint into the medullary canal.  Initially, the needle was used to remove some of the bone 
marrow to create volume for the cells, and then the cells were injected in saline solution. The 
Time Line Action 
Day = 0  Walker 256 cell culturing process (~2 week process) 
Day = 15  Intra-tibial injections of cancer cells (1 day process) 
Day = 36-42  MicroCT scans (confirmation of tumor-related lesions) 
Day = 47-56 1. Tail-injections of  99mTc-labeled  pamidronate 
2. Non-invasive mechanical loading  
3. Gamma camera scans 
4. Animal sacrifice and tissue harvesting 
Onward  Imaging analysis 
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needle was kept in place for ~2 minutes to prevent suspension egress, and a 10 µl volume of 
saline was used to push any leftover cell suspension from the needle cannula. The needle was 
removed and the injection site was closed using bone wax. The small skin incision was closed 
with surgical glue. Subcutaneous 0.05mg/kg of Buprenorphine (Buprenex 0.3mg/ml) was 
administrated after surgery. Extra dosages were applied if needed.   
 
2.2.4 In vivo microCT 21 days post-surgery to assess tumor growth: Each rat was 
anesthetized using isoflurane plus oxygen in an induction chamber. The rat was moved to the 
SPECT-μCT (X-SPECT Gamma Medica, Northridge, CA) and placed in a custom-made holder. 
A nose cone continued the administration of isoflurane plus oxygen for the duration of the scan 
at a lower concentration. A 45-minute microCT scan of 256 frames (projections) was taken. 
Preset values for voltage (100Kvolts) and current (100µamps) were used. System calibration 
(measurement of the position-dependent x-ray flux incident on the detector on air) and 
measurement of system background (measurement of the apparent x-ray flux with the x-ray tube 
off) were performed by  acquisition of “bright” and “dark” fields, respectively, immediately prior 
to imaging of each animal. After scanning, the rat was monitored until it regained consciousness. 
 
2.2.5 Radiotracer injection 29 days post-surgery: Rats were weighed and then 
anaesthetized as previously described. While keeping the animal warm with the use of a heat 
lamp, a tail injection of 
99m
Tc-labeled pamidronate at a dosage of 1mg/kg with an activity of 
approximately 250 MBq (7-9 mCi) dissolved in 0.8 ml of saline was administrated.  
 
2.2.6 Mechanical loading; drug delivery enhancement: As quickly as possible after 
injection, and keeping the rat anesthetized with ~2% isoflurane and 20% oxygen, the rat leg was 
positioned in the loading machine with a preload ~1N to hold the leg in position (Fig. 19). 10 
minutes of cyclic indirect, displacement-controlled non-invasive mechanical loading was applied 
to the rat tibia along its longitudinal axis with ~800 microstrain of deformation at a frequency of 
1Hz for a total of 600 loading cycles, a loading that imitates walking.  
Figure 19. Non-invasive loading device (TestBench 
ElectroForce, Bose Corp.). The rat tibia is constrained 
by foot and knee holders (blue arrows), while the 
actuator applies a sinusoidal compressive load (red 




2.2.7 Gamma camera scanning; uptake measurements: Immediately after loading and 
keeping the rat anesthetized, the rat was positioned in the microSPECT system in the custom-
made holder.  The gamma camera was placed as close as possible to the animal to enhance the 
spatial resolution. However, for proper comparison between samples, the gamma camera was 
placed at the same distance for all animals (Fig. 20, X2< X1, H2 gamma camera was used, X2 
equal for all animals). Planar gamma camera scans were taken for 45 minutes. Three sets of 
scans were taken for a total of 60 frames: 30 frames @ 10 sec each, 25 frames @ 60 sec each and 
finally 5 frames @ 180 sec each. After the imaging was finished, the rats were sacrificed by 











Figure 20. Rats were placed in the microSPECT system on a custom-made holder (black arrow) and 2D 
planar dynamic images were obtained from the gamma camera. In vivo gamma camera images were 
taken to assess pamidronate uptake after mechanical loading. Planar dynamic acquisition consisted of 3 
sets of scans - 30 frames @ 10 sec each, 25 frames @ 60 sec each and 5 frames @ 180 sec each – 
or a total of 60 frames over 45 min.   
 
2.2.8 Tissue harvesting: After sacrifice, the tibia and fibula were removed, keeping the 
surrounding tissue, including the skin. The harvest procedure was performed in an extremely 
delicate manner because excessive tissue handling can modify the activity distribution. All tissue 
was labeled properly for further studies. Excised tissue (tibiae, muscle, and skin) was placed in 
laboratory tubes, labeled and stored in a refrigerator for 24 to 36 hours.  
 
2.2.9 Data analysis: Gamma camera scans were analyzed by choosing anatomical regions of 
interest (ROI) as follows: 1) whole tibia ROI, 2) tibia head ROI with tumor area included and 3) 
SPECT 
system 
Laser alignment system  
Direction of movement  
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background ROI for calibration procedures (Fig. 21). Gamma camera data sets were properly 
corrected for radioactive decay and to the injected dose activity. Background count density 
(count per pixel) was subtracted from the count density in each ROI and the resulting count-rate 
data were expressed “per-gram” of tissue. Overall, gamma camera analysis consisted of mean 
cpm (counts per minute per pixel). Data from the closest gamma camera receiver (H2, see Fig. 
20) was analyzed because of its higher spatial definition. Equation 1 was used to find the mean 
activity increase between groups. Statistical analysis was performed using a student’s t-test to 
compare loaded tumor bearing tibiae activity levels to unloaded non-tumor-bearing tibiae 
activity levels (p<0.05). 
 





Figure 21. 2D gamma camera images. Three regions of interest (ROI) were analyzed for each rat:  the 
tumor site (A), the whole tibia (B) and the background (A and B). (C) An example of a 3D SPECT  
tomographic reconstruction fused with microCT images demonstrating radiolabeled pamidronate 
localization within the tibia. Because of time intensiveness and difficulty with co-registering the 3D-





2.3.1 Success rate of tumor formation: All animals survived the surgical procedure. 
Normal activity, locomotion and food and water consumption were seen in all rats. Few animals 
received subcutaneous buprenorphine administration to control pain a few days after surgery. 
Complete 3D analyses of the in vivo microCT scans obtained 21 days post-surgery 
demonstrated a 33% success rate for tumor induction.  Analysis of x-ray reconstructions 






demonstrated that the tibiae suffered from mixed lesions (see Fig. 22 for an example of sclerotic 
lesion). Bone deposits and smaller lytic endosteal lesions were seen within the bones that 
developed tumors. Pain control from tumor growth and bone destruction was not necessary; no 
tumors were allowed to develop into the cortical bone region. 
 
Figure 22. Rat 
microCT images 





image (left panel) 
2D MIP images (two 
right panels) of right 






2.3.2 Difference in drug delivery due to mechanical loading:  Gamma camera data 
analysis performed 29 days post surgery showed that non-invasive mechanical loading of the 
tumor bearing rat tibiae increased 
99m
Tc-labeled pamidronate delivery by 34.0% ± 7.5% in the 
tumor ROI and 28.9% ± 18.8% in the whole tibia ROI, when compared to unloaded non-tumor-






Whole tibia ROI Tumor ROI 
A B 
Figure 23. Average time activity curves for the loaded and control regions of interest for all rats as measured 
by gamma camera (mean ± SD). A) Tumor ROI and B) Whole tibia ROI.  cpm = counts per minute; 
measurements are scaled to the administered 
99m
Tc activity (in mCi). 









   
2.4 Discussion, conclusions and limitations 
 
The increased uptake of 
99m
Tc-labeled pamidronate reflects the increased pressure 
differences caused by the mechanical loading. The results demonstrate that mechanical loading 
can enhance drug delivery to tumors that would likely be clinically efficacious. While the results 
from this preliminary study are promising, the study has several limitations that will be 
overcome using improvements developed and described in Chapter 3. Future experimental 
improvements to the methods include 1) increased cancer cell viability after injection, 2) 
enhancement of cancer cell inoculation by arthrotomy surgery instead of direct tibial injection, 3) 
shifting from 2D planar SPECT to 3D microPET imaging, 4) use of tumor-bearing tibiae as 
controls, 5) use of the clinically relevant Herceptin as the injected drug, and 6) implementation 










Tumor ROI Whole tibia ROI 
B A 
Figure 24. Mean count activity for all time points for loaded versus control (n=12). A) Tumor ROI and 
B) Whole tibia ROI.  cpm = counts per minute; measurements are scaled to the administered 
99m
Tc 
activity (in mCi). Student t-test was implemented with a *p < 0.05. 
37 
 
Chapter 3 Development of Improvements in Project Methods 
 
3.1 Overview of planned changes  
The limitations seen in the pilot study directed us to evaluate and improve several aspects 
of the methodology of our approach including 1) optimizing cancer cell viability after injection, 
2) improving cancer cell inoculation surgery to enhance success of tumor formation, 3) shifting 
from 2D (planar) gamma camera imaging to 3D (tomographic) microPET to imaging to improve 
spatial resolution, 4) using tumor-bearing tibiae as controls, 5) using the clinically relevant 
Herceptin as the injected drug, and 6) implementation of high-resolution microCT and histology 
to assess bone destruction from tumor growth. These improvements, which will be used in 
upcoming planned experiments, are described in more detail below. 
 
3.2 Optimization of cancer cell viability 
3.2.1 Cell viability study: Because injection through a needle creates shear stresses on the 
cell membrane that could cause cell membrane rupture and death, a study was performed to 
investigate the viability of Walker 256 (W256) cells after injection through a syringe.  To mimic 
the previously performed experiments (injected cell density of 2.5M Walker 256 cells in 25µL of 
saline), the cell viability test consisted of utilizing W256 cells at two concentrations: 2.5 million 
cells per 25µL and 1.25 million cells per 25µL and two types of needle gauges: 28G and 22G. 
For control groups a standard micropipette was used for the injection. 
 Two frozen vials with a cell concentration of 5M W256 cells/mL were plated on t75 
flasks. After cell passage, six flasks were obtained that contained ~15M cells each, adding a total 
of ~100M cells. W256 cells were trypsinized, centrifuged and counted. The cell pellet was 
diluted into 1000µL of fresh media. From the 100M cells / 1000 µL solution, specific volumes 
were extracted with proper cell concentrations to be utilized for the viability test (Table 2).  
 
Concentration 1 (2.5M cells/ 25µL) & Concentration 2 (1.25M cells/ 25µL) 
22 Gauge Syringe 28 Gauge Syringe Control (Regular Pipette) 
Day 0 Volume = 25µL Day 0 Volume = 25µL Day 0 Volume = 25µL 
Day 1 Volume = 25µL Day 1 Volume = 25µL Day 1 Volume = 25µL 
Day 2 Volume = 25µL Day 2 Volume = 25µL Day 2 Volume = 25µL 
Day 3 Volume = 25µL Day 3 Volume = 25µL Day 3 Volume = 25µL 
Total 100 µL  100 µL  100 µL 
Table 2. Experimental setup for viability test. Cell concentrations and needles used, specific volumes and 
days of measurements are shown. 
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3.2.2 Injection procedure and cell death quantification: By removing the syringe plunger 
the cell suspension was introduced using a 2000µl micropipette. The 25µL cell suspensions were 
continuously injected (through the appropriate needle) at equal velocity and pressure into 
centrifuge tubes containing a specific volume of media. Cell number and viability were measured 
by cytometry. Analysis by light microscopy allowed for quantification of cell viability by the use 
of Trypan blue (volumetric ratio of 1:1), which stains dead cells. Cell viability quantification was 
completed on the same day of the test (Day 0= 0h), and after three successive days (Day 1=24h, 
Day 2= 48h and Day 3= 72h) in culture. 100mm dishes (surface area of 55cm
2
 and final holding 
cell concentration of 14M cells) were used for cell growth analysis. 
  
3.2.3 Results of cell viability study:  Cell death created by injection shear stress was zero 
except for the 28G syringe with the 2.5M cells/ 25µL concentration, where a ~4% cell death was 
observed. There was a decrease in cell number after injection through the 28G and 22G syringes 
compared to control values except for the 22G syringe with 1.25M cells/ 25µL concentration 
(Fig. 25). In terms of cell growth (Day 1-3), cells injected with the 28G syringe grew to a higher 












































































Figure 25. (Left) Walker 256 cell concentration right after injection.  (Right) There is a decrease in 
cell number after injection through the 28G and 22G syringes compared to control values except for 










































Figure 26. Cell concentration over time for the 2.5M cells/ 25µL injected concentration. Control (blue) shows 
highest initial cell concentration of 2.9M cells. Control has the lowest exponential growth rate of 0.5M/day. 28G 
needle (red) shows the lowest initial cell concentration of 1.6M cells, but has the highest exponential growth rate 
of 0.9M/day. 22G needle (green) shows median initial cell concentration of 2.3M cells and has the median 
exponential growth rate of 0.56M/day. Superimposed are fitting exponential trend lines of the data. M=1x10 
6
cells    
Figure 27. Cell concentration over time for the1.25M cells/ 25µL injected concentration. Control (blue) and 
22G needle show highest initial cell concentration of 1.3M cells and 1.6M cells, respectively. Control has the 
median exponential growth rate of 0.7M/day. 28G needle (red) shows the lowest cell concentration of 1.05M 
cells, but has the highest exponential growth rate of 0.85M/day.  22G has the median exponential growth rate 
of 0.56M/day. Superimposed are fitting exponential trend lines of the scatter data. M=1x10 
6
cells     
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3.2.4 Conclusions of cell viability test: The ~4% cell death after injection using the 28G 
syringe and 2.5M cells/ 25µL concentration was likely caused by the high cell density and small 
needle inner diameter. The decrease of cell quantity injected with the 28G needle (Fig. 25) 
suggests that cells are attaching rapidly to the syringe/needle wall or clumping together at the 
needle opening. This decrease is relevant as the number of cells being delivered into the rat tibia 
is smaller than expected. The 22G needle with 1.25M cells/ 25µL concentration showed no 
decrease in cell number compared to control; thus the 22G syringe needle will inject a greater 
number of live cells compared to the 28G needle.  
Overall, a larger needle inner diameter and lower cell concentration will provide the 
greatest cell viability and delivery, as seen in the combination of 22G needle and 1.25M 
cells/25µL. However, considering other factors such as bone destruction caused by the needle as 
well as the restricted space inside the tibia, a 24G needle will be used in future experiments.   
 
3.3 Improvement of cancer cell inoculation surgical technique  
Injection of cancer cells into the tibia medullary cavity by direct injection is a complex 
process. The cells need to be inoculated in the core of the medullary canal a few millimeters 
below the growth plate. The difficulty in accessing the proximal tibia reduces the probability of 
localized tumor formation. Arthrotomy is a commonly used technique that entitles the 
dislocation of the knee to improve access into the knee joint. The inoculation requires the 
detachment and displacement of the knee cap (without tearing the patellar ligament) and 
surrounding tissue for the needle to be inserted at the intercondylar eminence at the proper angle 
(Stepensky et al., 2002), to pierce perpendicular to the bone surface (Kurth et al., 2000). To 
implement this procedure, a small rostro caudal 1 to 1.5 cm superficial incision will be made 
along the lateral collateral ligament avoiding deep cuts to prevent injury (Mao-Ying et al., 2006). 
With the small incision in place and making sure that ligaments and tendons are aside while 
maintaining the leg in a straightened position, a scalpel will be used to separate the knee cap 
from the femur via a single cut to avoid collateral tissue damage. Maintaining the leg unbent and 
using low pressure, the knee cap will be pushed medially, until the dislocation takes place. Once 
the knee cap is dislocated, the leg can be flexed and twisted to expose the tibia head.  
By avoiding the meniscus, the 24G needle can pierce through the cartilage and bone. Using a 
slow drilling motion of the needle (without removing the stylet to prevent clothing), the needle 
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will be inserted 5 to 7 mm below the knee joint into the medullary canal (Mao-Ying et al., 2006). 
Prior to W256 cell injection, the stylet will be removed and an empty syringe will be connected 
to the 24G needle to remove some marrow to create an empty space for the W256 cells. After 
that, the syringe with marrow will be removed and the 24G needle will be connected to a glass 
syringe containing 1.25x10
6
 W256 cells per 25 μL. The cell suspension will be injected and the 
needle will be maintained in the bone to prevent cell suspension egress. After 1 to 2 min the 24G 
needle will be removed. The injection site will be closed with bone wax and veterinarian glue. 
Even though this surgical technique is more invasive than the direct injection previously 
described, the benefits of this technique overpass its risks. This surgical technique will be used in 
future experiments to increase the tumor formation success rate. 
 
3.4 Use of tumor-bearing tibiae as controls 
In our pilot study, controls were the contralateral, unloaded tibiae that had not received 
cancer cell inoculation. This control group lacked the injury caused by the needle, the tumor 
formation, and the bone destruction caused by tumor growth. Therefore, non-inoculated tibias 
are not proper samples for comparison. Consequently, controls will be rats with developed 
tumors after cancer-cell injections that are not subjected to mechanical loading.  
 
3.5 From 2D to 3D: microPET imaging 
Even though our preliminary results using gamma camera imaging are promising, a more 
sensitive, more specific and more easily quantifiable system is needed. In future studies we will 
use microPET, which can improve all the above mentioned parameters that the gamma camera 
does not have.  
 PET is now a widely used imaging modality in cancer (Zanzonico, 2004) particularly for 
staging, and monitoring response after therapy (Martinez, 2008). Compared to single-photon 
(planar and SPECT) imaging, PET provide greater quantitative accuracy, better spatial 
resolution, and higher sensitivity.  Clinically, PET has a lower incidence of false positives 






Tc-HMDP) (Ito et al., 
2007).  
PET works on the theory of annihilation coincidence detection (ACD) of two collinear 
511KeV gamma rays formed by the annihilation of a positron and negatron (Zanzonico, 2004; 
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Martinez et al., 2008) (Fig. 28). True coincidences are accounted as pair annihilation; however, 
there exist random and accidental events that reduce the image quality. The type of isotope used, 
detector material and configurations, time windows of detection, computer processing power and 
other mechanisms can be used to improve the system performance, sensitivity and spatial 
resolution (Zanzonico, 2004; Martinez et al., 2008).  
Figure 28.  Positron (β+) 
emitting radionuclides have 
structurally unstable nuclei due 
to a deficiency of neutrons (or 
excess of protons) that approach 
stability through the conversion 
of a proton (p) into a neutron (n) 
and emission of a positron 
electron (e
+
When the positron (e+) comes to 
rest in the surrounding, usually 
within several millimeters or less of the site of emission, it interacts electrostatically  with an orbital 
electron (e-) of an atom in the surrounding tissue. The positron and electron annihilate each, converting 
their rest mass energies to electromagnetic radiation and thus emitting   two 511-keV γ-rays back to back, 
which are detected by the coincidence circuitry of the PET scanner. From Zanzonico, 2004; equation 
from Martinez et al., 2008. 
 
Characterization of lytic, sclerotic and mixed lesions of prostate cancer with metastases 










F-fluoride as a cocktail. This method showed an enhanced detection of 
bone cancer (Iagaru et al., 2008). Morphologic and metabolic analyses have also been used with 
PET and bone cancer using 
18
F-fluoride (Kawaguchi et al., 2010), in addition to histological 
responses to chemotherapy using 
18





F-fluoride (Arvanitis et al., 2008).     
3D microPET imaging instead of gamma camera  planar scans used in our preliminary 
study will provide higher spatial resolution, 3D quantifiable images of drug distribution, and the 






Zr-Herceptin. We have 
performed a trial imaging protocol using the small animal PET scanner at MSKCC with 
18
F-





Figure 29. Small animal PET images of a rat 
lower body. Left: Hemibody 3D projection. 
Right: Coronal view slice demonstrating a 
region of interest (ROI) of the tibia (dashed 
lines). 3D volumes of interest were created over 
contiguous tomographic sections to yield 
volumetric activity data.  
 
 
3.6 Herceptin as the new injected drug  
 Herceptin, also known as trastuzumab, is a human epidermal receptor (HER2/neu) 
monoclonal antibody (Robert and Favret, 2007; Gutierrez and Schiff, 2011) approved by the 
FDA. Herceptin is used in patients suffering from cancer that overexpresses the HER receptor. 
HER2 receptor is associated with signal transduction pathways involving cell survival and 
growth (Robert and Favret, 2007; Gutierrez and Schiff, 2011).  A clinical trial of Herceptin in 
patients suffering from metastatic breast cancer showed an improvement on the progression-free 
survival rate (50% vs. 30% (p<0.01); Robert and Favret, 2007).  
Herceptin has been used in nuclear medicine as an inmunoPET imaging tracer (Dijkers et 
al., 2009; Holland et al., 2010). Herceptin can be radiolabel with 
89
Zr, and in vivo distribution of 
89
Zr-labeled trastuzumab has been measured in healthy and tumor tissue in mice (Dijkers et al., 
2009; Holland et al., 2010). 
89
Zr-labeled trastuzumab can be radiolabeled in a stable manner; 
systemic blood and tissue clearance is fast. Tumor uptake is slow when compared to small 
tracers, but it increases greatly over time.  
 For our future work, Herceptin will be used with W256 cells. Herceptin was chosen 
because of its clinical significance as well as its relatively large size (~145 kDa), which should 
enable enhanced convection due to loading without binding in the Walker 256 tumor model 
(Flessner et al., 2005). Given that W256 do not express HER receptors (Blouin et al., 2005), 
Herceptin can be used as a non-specific radiotracer. The effects of mechanical deformation 
should have a greater enhancement for larger molecules compared to smaller ones such as 















3.7 High resolution microCT and histology to assess bone tumors 
 While the in vivo microCT scanner is effective for visualizing the developing tumor, it 
does not have sufficient resolution to accurately assess the volume of the tumors and the effects 
on the bone microarchitecture.   
Guidelines for high-resolution micro-computed tomography assessment in small animal 
models of bone have been given in several research articles such as Bouxsein et al. (2010). Using 
these guides a scanning, reconstruction and analysis protocol has been developed for use in 
future experiments to assess bone tumors after sacrifice.   
Harvested tibiae containing tumors will be scanned using a Skyscan 1172 microCT 
scanner (Skyscan, Belgium). Attenuation corrections will be performed according to the power 
setting to be used by means of bright and dark field calibrations to air x-ray attenuation. Scans 
will be completed within a low-attenuation-plastic holder filled with PBS. Nominal isotropic 
voxel resolution of about ~1-4 μm will be used. Short step degrees, multiple averages and filters 
can be used to improve the signal to noise ratio. 
 Through image processing the x-ray projections will be reconstructed into 8 bit bmp or 
18 bit tiff images. Compensations for misalignment, ring artifacts, and beam hardening will be 
completed to increase image quality. Hydroxyapatite rods (2 mm diameter, densities of 0.25 and 
0.75 g/cm³) will also be scanned to obtain tissue mineral density (TMD). Measurements such as 
BMD, trabecular and cortical porosity (connectivity and volume), trabecular volume, trabecular 
and cortical surface area, trabecular connectivity, moments of inertia, trabecular and cortical 
thickness, trabecular length and spacing, and degree of anisotropy will be calculated.  
In addition to high resolution microCT, histology will be used as another tool for 
assessment of tumor morphology, type and volume. Histology can provide detailed information 
on the morphological local effects on drug delivery, correlations between drug uptake and tumor 
type (sclerotic, lytic or mixed) and the effects of tumor volume on drug distribution. Histological 
analysis of the tumors will be performed using plastic and paraffin-embedding with H&E to 
quantify tumor morphology and pathology. 
 
3.8 Summary of planned experiments 
Using the improvements described above, the next set of experiments will more 
completely assess whether mechanical loading can enhance drug delivery to bone tumors. 
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Briefly, our planned experiments include the following: quantification of the effectiveness of 









F-fluoride will be used to image drug uptake into the bone tumor 
extracellular matrix, 
18
F-FDG will be used to quantify uptake into the bone tumor cells and 
89
Zr-
Herceptin will be used to assess non-specific convective drug delivery. Because of the short half 






F-FDG can be imaged consecutively as long as previous 
activity has decayed.   
 Drug uptake into rat bone tumors will be quantified after mechanical load application 
using the non-invasive loading device (Table 4). A time line will be implemented as follows 
(Table 3): 




F-FDG can be used in sequential scans 




Time Line Action 
Day = 0  Walker 256 cell culturing process (~2 week process) 
Day = 1  Intra-tibial injections of cancer cells (1 day process) 
Day = 21  MicroCT scans (confirmation of tumor-related lesions) 





-No mechanical loading (Time point 1) 





-No mechanical loading (control group) 
-3D microPET scans 
-Animal sacrifice and tissue harvesting 
 





-Mechanical loading (Time point 2) 





-Mechanical loading (experimental group) 
-3D microPET scans 
-Animal sacrifice and tissue harvesting 
 
Day = 57 a) Dose calibrator measurements 
b) Scintillation counter measurements 
Onward  Imaging analysis 
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Table 4. Experimental set up for specific aim 1. N/A= non-applicable. 
 
3.9 Translation to the clinic: Positive results using this approach could enhance the 
treatment of bone tumors, resulting in an improvement in the quality of life for patients suffering 
from bone metastasis. Future studies are planned to address the long-term goal of developing a 
clinical protocol that uses load-bearing exercise, e.g., slow treadmill walking or stationary 
bicycling, as a new chemotherapy and or immunotherapy treatment adjunct.  This low-risk and 
easy-to-implement approach may enhance a drug’s clinical effect while potentially decreasing 
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N/A microPET 0 
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